Sign in Subscribe
Cancer metastasis

Prognostic Factors Identified for Metastatic Castration-Resistant Prostate Cancer Undergoing Radioligand Therapy

Strategic Insights

— 2 min read

New research conducted at the Department of Nuclear Medicine, Balikesir Ataturk City Hospital in Turkiye has shed light on the prognostic factors for metastatic castration-resistant prostate cancer (mCRPC) patients undergoing 177Lu-PSMA-617 radioligand therapy. The study retrospectively examined 31 patients with median age 69 (57-80) years, who received treatment between 2021 and 2024. The findings indicate that the presence of visceral metastasis, fatigue, anorexia, and nephropathy are significantly associated with poor overall survival. In a multivariate model, visceral metastasis, fatigue, and nephropathy remained significant prognostic factors.

Key Takeaways:

  • The study retrospectively examined 31 patients with metastatic castration-resistant prostate cancer (mCRPC) who underwent 177Lu-PSMA-617 radioligand therapy between 2021 and 2024.
  • The presence of visceral metastasis, fatigue, anorexia, and nephropathy were significantly associated with poor overall survival.
  • In a multivariate model, visceral metastasis, fatigue, and nephropathy remained significant prognostic factors for overall survival.
  • Patients with visceral metastases had an overall survival of 20.79 months (95% CI: 16.77-24.81; p = 0.001).
  • Patients with anorexia had an overall survival of 15.57 months (95% CI: 7.17-23.97; p = 0.036).
  • Patients with fatigue had an overall survival of 13.32 months (95% CI: 5.39-21.25; p = 0.023).
  • Patients with nephropathy had an overall survival of 14.96 months (95% CI: 6.22-23.70; p = 0.038).
  • The study was conducted at the Department of Nuclear Medicine, Balikesir Ataturk City Hospital, Turkiye, and involved 31 patients with a median age of 69 (57-80) years.
  • The research has been peer-reviewed and published in the Jcpsp-journal of the College of Physicians and Surgeons Pakistan.

Statistics:

  • 31 patients with metastatic castration-resistant prostate cancer (mCRPC) underwent 177Lu-PSMA-617 radioligand therapy between 2021 and 2024.
  • 74.2% of patients experienced at least one adverse event, while 22.6% experienced serious adverse events.
  • Patients with visceral metastasis had an overall survival of 20.79 months (95% CI: 16.77-24.81; p = 0.001).
  • Patients with anorexia had an overall survival of 15.57 months (95% CI: 7.17-23.97; p = 0.036).
  • Patients with fatigue had an overall survival of 13.32 months (95% CI: 5.39-21.25; p = 0.023).
  • Patients with nephropathy had an overall survival of 14.96 months (95% CI: 6.22-23.70; p = 0.038).

Sources:

  • Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177Lu-PSMA-617 Radioligand Treatment. Jcpsp-journal of the College of Physicians and Surgeons Pakistan, 2025;35(10):1261-1268.
  • Hasan Bozkurt, Dept. of Nuclear Medicine, Balikesir Ataturk City Hospital, Balikesir, Turkiye.
  • Coll Physicians & Surgeons Pakistan, Seventh Central St, Defence Housing Authority, Karachi, 75500, Pakistan.

Read more